Global Health Corps

MedX Health and PharmaChoice Announce Agreement to Launch MedX Teledermatology Screening Platform Across Canada

Retrieved on: 
Tuesday, April 18, 2023
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Global Health Corps, Ontario Basic Income Pilot Project, Pharmacy, Aircraft pilot, Dermatology, Moles, User experience, Spectrophotometry, The Company, Patient, PharmaChoice, Medarex, Medical imaging

Initially, the Pilot Project will be conducted at twenty (20) PharmaChoice locations in four Provinces: British Columbia, Ontario, Nova Scotia and Newfoundland.

Key Points: 
  • Initially, the Pilot Project will be conducted at twenty (20) PharmaChoice locations in four Provinces: British Columbia, Ontario, Nova Scotia and Newfoundland.
  • Depending on assessments, success and demand, the Pilot Project may be expanded up to fifty (50) locations across Canada.
  • Upon successful completion of the Pilot Project, PharmaChoice and MedX anticipate that access to MedX’s teledermatology screening service will be rolled out across the entire PharmaChoice chain of pharmacies.
  • “PharmaChoice Canada is delighted to partner with MedX in bringing its leading teledermatology assessment and screening technology to the communities that we serve,” stated Curtis Chafe, Vice President.

Goldman Sachs x Robin Hood Inaugural Rising Leaders Forum Attracts Nearly 300 Young Investors to Chart Philanthropic Impact

Retrieved on: 
Thursday, January 26, 2023
Athlete, Goldman Sachs, Global Health Corps, Hunger, Poverty, University, Education, Student, Life, Robin, IT Leader Forum, Entrepreneurship, Woman, NBA, Growth, Homelessness, GDP, Robin Hood, Tudor Investment Corporation, Lincoln Center, Blue Ridge Capital, Organization, Small business, Sustainability, Avenue Capital Group, Cryptocurrency, Film industry, Management, New Yorker

NEW YORK, Jan. 26, 2023 /PRNewswire/ -- Robin Hood, the largest philanthropy focused on fighting poverty in New York City, joined forces with Goldman Sachs, a premiere global banking and investment institution, to present the Rising Leaders Forum, an invitation-only event for rising investors and philanthropists. The inaugural forum for young leaders included sessions with CEOs, leading philanthropists, academics, activists, and athletes —all of whom are focused on making a sustainable impact in New York and across the globe. Nearly 300 of the top investing, entrepreneurial, and innovative thinkers shared insights and case studies on data-driven grant-making, public-private partnerships, and the role of advocacy.

Key Points: 
  • "The participants in the Rising Leaders Forum, like Robin Hood's donors and supporters, want to make sure that one's starting point in life does not define where one ends up.
  • The Rising Leaders Forum builds upon Goldman Sachs' long record of driving inclusive growth through strategic philanthropy.
  • Goldman Sachs Gives, has created signature initiatives supporting the most innovative leaders in the global philanthropic sector with over $2 billion in grant-making.
  • This year's forum showcased impact in action by sharing the model used by Robin Hood.

MedX Health Confirms Further Interim Closing and Application for Further Extension of Price Protection for Private Placement Convertible Loan Note Financing

Retrieved on: 
Friday, September 9, 2022
Research, Technology, Medical Devices, FDA, Software, Biotechnology, General Health, Health, Science, Other Science, Private placement, Price, Regulation of tobacco by the U.S. Food and Drug Administration, Therapeutic Goods Administration, Closed-end fund, TSX Venture Exchange, Medarex, Physician, Food, Union, Health Canada, TSX, Moles, Funding, Company, Stock exchange, Press release, Global Health Corps, Private, Light, Dermatology, Media release, Security (finance)

No Cash Commissions or Agents Warrants were paid or issued in relation to those seven Convertible Notes.

Key Points: 
  • No Cash Commissions or Agents Warrants were paid or issued in relation to those seven Convertible Notes.
  • Securities issued on are subject to a four month restriction from trading in accordance with relevant regulatory and stock exchange policies.
  • The Company also has further subscriptions in hand for $500,000 which are in process of being funded, and additional subscriptions are anticipated.
  • SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility.

Optimi Health Signs First International Mushroom Supply Agreement with UK-based Avida Global

Retrieved on: 
Wednesday, September 7, 2022
Phrase, MDMA, Health Canada, Form, News, Global Health Corps, Health, Patient, Risk management, Psilocybin

Optimi Health Corp. is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets.

Key Points: 
  • Optimi Health Corp. is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets.
  • Avida Global is a vertically integrated Global cannabis business headquartered in Surrey, UK, with a dedicated cultivation and production facility in North-East Colombia.
  • The Avida Global Group consists of Avida Global SAS, Avida Labs UK and Green Stem CBD.
  • Avida Labs is Avida Globals white-labelling and manufacturing business.

Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of Directors

Retrieved on: 
Thursday, August 25, 2022
Form, Health Canada, News, Phrase, MDMA, Global Health Corps, Health, Risk management, Psilocybin

Optimis products are grown at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia, making it the largest psilocybin and MDMA cultivator in North America.

Key Points: 
  • Optimis products are grown at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia, making it the largest psilocybin and MDMA cultivator in North America.
  • This news release contains forwardlooking statements and forwardlooking information within the meaning of Canadian securities legislation (collectively, forwardlooking statements) that relate to Optimis current expectations and views of future events.
  • Optimi undertakes no obligation to update or revise any forwardlooking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
  • Any forwardlooking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

MedX Announces Final Acceptance of Issuance of Series II Convertible Loan Notes

Retrieved on: 
Tuesday, June 21, 2022
Software, Research, General Health, Telemedicine, Virtual Medicine, Technology, Genetics, Science, Biotechnology, FDA, Telecommunications, Other Science, Health, Therapeutic Goods Administration, TSX, Union, Moles, Regulation of tobacco by the U.S. Food and Drug Administration, Note, Notice, Global Health Corps, Company, Health Canada, Media release, Finance Secretary (India), Exercise, Physician, Medarex, Indian stock exchange, Light, Dermatology, Food, TSX Venture Exchange, Series, Security (finance), Holder

MedX Health Corp. (MedX or the Company) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that it has received final Acceptance from the TSX Venture Exchange in respect of the Closing of the placement of Series II Convertible Notes that took place on March 21, 2022, and which comprised issuance of 20 Series II Convertible Notes, and raised a total of $1 Million.

Key Points: 
  • MedX Health Corp. (MedX or the Company) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that it has received final Acceptance from the TSX Venture Exchange in respect of the Closing of the placement of Series II Convertible Notes that took place on March 21, 2022, and which comprised issuance of 20 Series II Convertible Notes, and raised a total of $1 Million.
  • The Series II Convertible Notes bear interest at 8% per year, payable Half-yearly, and will mature on December 31, 2026 (the Maturity Date).
  • The Series II Convertible Notes may be converted, at the option of the Holder, into units at $0.10 per unit (Series II Unit) at any time until the Maturity Date.
  • Each Series II Unit will be comprised of One (1) fully paid Common Share and One-half (1/2) of a Series II Share Purchase Warrant.

Optimi Health Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics

Retrieved on: 
Monday, June 20, 2022
Psilocybin, FOR, Global Health Corps, Form, Health, News, EU, Phrase, Risk management

Optimi Health Corp. is a homegrown, Canadian success story producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets.

Key Points: 
  • Optimi Health Corp. is a homegrown, Canadian success story producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets.
  • FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:
    This news release contains forwardlooking statements and forwardlooking information within the meaning of Canadian securities legislation (collectively, forwardlooking statements) that relate to Optimis current expectations and views of future events.
  • Optimi undertakes no obligation to update or revise any forwardlooking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
  • Any forwardlooking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

MedX Health Adds New Board Member

Retrieved on: 
Tuesday, June 14, 2022
Health, Medical Devices, Technology, Telemedicine, Virtual Medicine, Health Technology, Telecommunications, Biotechnology, United Kingdom, Moles, Company, Pharmacy, Board of directors, Therapeutic Goods Administration, Telehealth, Spectrophotometry, Johnson & Johnson, Skin cancer, TSX Venture Exchange, Food, Gulf Cooperation Council, Medtronic, Aesthetics, CEO, Partnership, Brisbane Diamantina Health Partners, Dermatology, Physician, Medarex, Growth, Health Canada, Technology, Economics, Adoption, TSX, Emirates, Diagnosis, Union, Media release, United Arab Emirates, Board, Global Health Corps, Light, Regulation of tobacco by the U.S. Food and Drug Administration, Management, Pharmaceutical industry, Medical device

MedX Health Corp. (MedX or the Company) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that Naman Demaghlatrous has been appointed to its Board of Directors.

Key Points: 
  • MedX Health Corp. (MedX or the Company) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that Naman Demaghlatrous has been appointed to its Board of Directors.
  • The partnership with Health Partners in the United Kingdom, currently conducting its pilot program, represents the Companys first foray into the occupational health vertical.
  • MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology.
  • SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility.

MedX Health Applies for Further Extension of Price Protection for Private Placement Convertible Loan Note Financing

Retrieved on: 
Thursday, May 12, 2022
Oncology, Health, Medical Devices, Technology, Software, General Health, Biotechnology, Convertible, Physician, Notice, Dermatology, Company, Private placement, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Global Health Corps, Exercise, TSX Venture Exchange, Placement, Light, Private, Price, TSX, Finance Secretary (India), Stock exchange, Medarex, Therapeutic Goods Administration, Union, Media release, Indian stock exchange, Health Canada, Moles, Funding, Security (finance), Holder

The Financing is a non-brokered Private Placement to accredited investors of up to $4 million by issuance of up to 80 Convertible Loan Notes, each with a face value of $50,000 (Convertible Notes).

Key Points: 
  • The Financing is a non-brokered Private Placement to accredited investors of up to $4 million by issuance of up to 80 Convertible Loan Notes, each with a face value of $50,000 (Convertible Notes).
  • The Convertible Notes will bear interest at 8% per year, payable Half-yearly, and will mature on December 31, 2026 (the Maturity Date).
  • The Convertible Notes may be converted, at the option of the Holder, into units at $0.10 per unit (Unit) at any time until the Maturity Date.
  • Each Unit will be comprised of One (1) fully paid Common Share and One-half (1/2) of a Share Purchase Warrant.

Guggenheim Partners Accepting Applications for Fourth Network for Social Innovation Cohort

Retrieved on: 
Tuesday, April 19, 2022
Corporate social responsibility, Social innovation, Guggenheim Partners, Intention, Interest, Network, Organization, GLOBE, Sanitation, LinkedIn, Growth, Social Problems, Pursuit, NSI, Global Health Corps, SIRUM, Public relations, Guggenheim

NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Guggenheim Partners is now accepting applications for the fourth cohort of the Network for Social Innovation (NSI), the firms venture philanthropy program designed to identify and support the growth of visionary non-profit organizations tackling some of the most challenging issues of our time.

Key Points: 
  • NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Guggenheim Partners is now accepting applications for the fourth cohort of the Network for Social Innovation (NSI), the firms venture philanthropy program designed to identify and support the growth of visionary non-profit organizations tackling some of the most challenging issues of our time.
  • Through the Network for Social Innovation, Guggenheim Partners invests $100,000 in several high-performing, early-stage, non-profit organizations leveraging innovative solutions to solve enduring social problems.
  • Since launching the initiative in 2016, Guggenheim has supported 15 non-profit organizations through the Network for Social Innovation and looks forward to expanding the cohort in 2022.
  • The Network for Social Innovation is a signature component of Guggenheims efforts to invest in the communities where we serve our clients and where our employees work and live, said Robert Rutkoff, Head of Corporate Social Responsibility at Guggenheim Partners.